Malignant serous cavity effusion
Conditions
Interventions
Sponsors
Beijing University of Chinese Medicine Shenzhen Hospital (Longgang)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) The diagnosis of malignant hydrothorax and ascites was confirmed by histopathology or cytological examination of hydrothorax and ascites. (2) There was no antineoplastic treatment within one month before treatment and no contraindications for the use of pleural and abdominal biological response regulators. (3) The estimated survival time is more than 3 months, and the KPS score is more than 60. (4) With the age of 18-75 years old, regardless of sex. (5) Informed consent was signed and volunteer for treatment.
Exclusion criteria
Exclusion criteria: (1) Those who complicated with cardiovascular, kidney, hematopoietic system and other serious primary diseases or psychosis. (2) Pregnant or lactating women, those who are allergic constitution and allergic to drugs. (3) Those who cannot use drugs in accordance with the regulations, so that it's unable to judge the efficacy of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life;Therapeutic effect of TCM syndromes;Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;progress Free Survival;ATPPase expression in serum, hydrothorax and ascites;SDHPase expressiom in serum, hydrothorax and ascites;CEA expression iin serum, hydrothorax and ascites;CA125 expression in serum, hydrothorax and ascites;VEGF expression in serum, hydrothorax and ascites;CD3+ expression in serum, hydrothorax and ascites;CD8+ expression in serum, hydrothorax and ascites; | — |
Countries
China
Contacts
Public ContactFeng Gaofei
Beijing University of Chinese Medicine, Shenzhen Hospital
Outcome results
None listed